It was nice to hear one healthcare executive and investor after another respond to the question, “what are your key priorities when evaluating a deal?” with the answer, “really compelling science.”
I’ve often heard VCs and angel investors cite the importance of large addressable markets and talented executive teams as key considerations to a deal, along with compelling technology. But the different dynamics among different investors really came to the surface at today’s Life Science Nation’s Redefining Early-Stage Investments conference in Boston, which focused on alternative sources of funding…
